Emkay Global Financial is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 835 in its research report dated June 04, 2020.
Emkay Global Financial's report on Aurobindo Pharma
Q4 was solid on strong execution across markets (5% revenue beat), sharp gross margin expansion (+290bps qoq) and debt reduction (-US$87mn qoq). EBITDA was 12% higher, while margins were 130bps above estimate at 21.4%. US was in line but mix was weak, with lower injectables/higher Oral solids. Q1 should see a qoq fall, but FY21 trajectory should continue with 50-60 launches (25 already approved). Outside the US, ARV should continue to remain strong with recent tender wins. Key positives from Q4 results/commentary: 1) debt to shrink by US$200-250mn in FY21 and ARBP to be debt-free by FY22, 2) US momentum to stay with 50+ filings/launches, 3) gross margin trajectory to improve to 58-59%, if INR/USD stays at current levels.
Outlook
We upgrade FY21/22E EPS by 6%/4% and revise TP to Rs835, as we roll over to 15x Jun’22E EPS. Retain Buy and maintain significant OW in EAP. Key risk: any meaningful slowdown in the US trajectory/regulatory issues in key plants.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Read More
